It’s safe to say the healthcare sector isn’t renowned as a repository of dividend-paying companies.
Yet some not only pay such monies steadily and reliably, but theirs are lofty enough to be considered high-yield dividends
And, per their established habit, they’ll surely be declaring dividend raises before long. Here’s a brief look at a pair of such stocks: AbbVie (NYSE: ABBV) and Medtronic (NYSE: MDT). AbbVie (current dividend yield: 3.3%) Pharmaceutical stock investors tend to focus on the dreaded patent cliff.
This is the point at which a drug loses its patent exclusivity and therefore becomes vulnerable to competition from any rival willing to reproduce the molecule. Earlier this decade, the web of patents protecting AbbVie’s versatile blockbuster drug, Humira, began to expire, sparking concerns that it would make the company an also-ran. This didn’t occur; in fact, AbbVie these days is thriving more than it did during the height of the drug’s exclusivity and popularity.